Issue Autumn 2024Signs of recoveryThe first half of 2024 is history, and experts are divided on whether the financing nadir has been reached or even passed. There are very different figures for different types of treatments under development. … more ➔
Issue Summer 2024Organ-on-a-chipThe Three R (Replacement, Reduction and Refinement) principles developed over 60 years ago provide a framework for more humane lab animal testing and, more importantly, less of it. A range of in-vitro … more ➔
Issue Spring 2024Targeted radiotherapy powered by BiotechRadiopharmaceuticals have turned into a hot commodity when it comes to M&A financing and deals. Targeted therapies that employ high-energy attachments linked to antibodies, small molecules or peptides … more ➔
Issue Winter 2023Cellular Agriculture – Boom or exodus?Will Europe once again grow dependent on the US and Asia – this time in the potential billion-dollar market for cell-based meat, fish and dairy products? Over 90% of EU biotechs with a corresponding … more ➔
Issue Autumn 2023Cell & Gene Therapy – Getting Europ...Cell and Gene Therapies (CGTs) have emerged as one of the fastest growing sectors in the life sciences industry, even though supply chains in the field are more complex than in traditional pharma. That’s … more ➔
Issue Summer 2023Faster smarter clinical trailsAlthough 18 million people die of cardiovascular diseases every year, the pharma industry has limited its clinical research on new heart drugs for cost reasons. To gain market approval in the past, tens … more ➔
Issue Spring 2023Synthetic Biology: Green new worldNearly thirty years ago, Bill Gates commented that “DNA is like a com- puter program, but far more advanced than any software ever created.” That recognition, however, was only the first step on … more ➔
